Drug Type TCR therapy |
Synonyms Autologous, engineered T Cells targeting TP53 R248Q(Shanghai General Hospital), TP53 R248Q Mutation-specific TCR-T Cell Therapy(Shanghai General Hospital) |
Target |
Mechanism p53 modulators(Tumor protein p53 modulators) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseEarly Phase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Adenocarcinoma of Lung | Phase 1 | CN | 24 Sep 2024 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 24 Sep 2024 | |
Colorectal Cancer | Phase 1 | CN | 24 Sep 2024 | |
Pancreatic Cancer | Phase 1 | CN | 24 Sep 2024 |